Keeping Track: US FDA Approves Sanofi’s Dengvaxia, But Heron’s HTX-011 And Nabriva’s Contepo Fall Short

Here's your US review and approval news for the week in brief: The FDA’s Center for Biologics Evaluation and Research announced its third novel biologic approval of 2019 on 1 May, clearing dengue vaccine Dengvaxia on its first review cycle – but for only a slice of the population sought by Sanofi.